Compare QTWO & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QTWO | GPCR |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2014 | 2023 |
| Metric | QTWO | GPCR |
|---|---|---|
| Price | $54.61 | $49.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $82.64 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 808.0K | 697.0K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $193,978,000.00 | N/A |
| Revenue This Year | $12.48 | N/A |
| Revenue Next Year | $10.18 | N/A |
| P/E Ratio | $132.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.79 | $15.80 |
| 52 Week High | $92.66 | $94.90 |
| Indicator | QTWO | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 50.72 |
| Support Level | $54.64 | $43.76 |
| Resistance Level | $56.24 | $57.15 |
| Average True Range (ATR) | 2.23 | 2.73 |
| MACD | -0.00 | -0.61 |
| Stochastic Oscillator | 69.56 | 36.26 |
Q2 Holdings Inc provides digital solutions to financial institutions, financial technology companies, and alternative finance companies, seeking to incorporate banking into their customer engagement and servicing strategies. The company helps its clients with supervisory, consumer protection, privacy, third-party risk management requirements, and cyber threats and fraud, among other applications, by offering a portfolio of digital solutions, which comprises its digital banking offerings, digital lending and relationship pricing solutions, risk and fraud solutions, as well as Q2 Innovation Studio and Helix. Q2 derives the majority of its revenue from subscription fees for the use of its hosted solutions.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.